Skip to main content
Erschienen in: Annals of Hematology 7/2012

01.07.2012 | Original Article

Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin’s lymphoma patients

A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL)

verfasst von: Luigi Rigacci, Benedetta Puccini, Sergio Cortelazzo, Gianluca Gaidano, Andrea Piccin, Alfonso D’Arco, Roberto Freilone, Sergio Storti, Enrico Orciuolo, Pier Luigi Zinzani, Francesco Zaja, Velia Bongarzoni, Monica Balzarotti, Delia Rota-Scalabrini, Caterina Patti, Marco Gobbi, Andrea Carpaneto, Anna Marina Liberati, Alberto Bosi, Emilio Iannitto

Erschienen in: Annals of Hematology | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Bendamustine is an alkylating agent with a nitrogen mustard group and a purine-like benzimidazole group. The aim of this study was to collect all the Italian experiences with this drug in order to evaluate the results in term of response to therapy and toxicities. We analyzed lymphoma patients treated in 24 Italian haematological centres with bendamustine alone or in combination with anti-CD20 antibody. One hundred seventy-five relapsed or refractory lymphoma patients were enrolled. The median age was 69 years (range 26–87). Seventy-nine patients were relapsed, 35 were refractory and 61 presented a progressive disease after partial response. The diagnoses were 60 indolent non-follicular lymphomas, 34 diffuse large B-cell lymphomas, 48 follicular lymphomas, 30 mantle cell lymphomas and three peripheral T-cell lymphomas. All patients were evaluable for response: 52 (29%) with complete remission, 72 (43%) with partial response with an overall response rate of 71%, and 51 non-responders. With a median observation period of 10 months (1–43), 70% of patients are alive. In summary, this retrospective study shows that treatment with bendamustine alone or in combination with rituximab is a safe and effective regimen in a subset of multi-resistant patients.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics 2008. CA Cancer J Clin 58:71–96CrossRef Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics 2008. CA Cancer J Clin 58:71–96CrossRef
2.
Zurück zum Zitat Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481–488CrossRef Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481–488CrossRef
3.
Zurück zum Zitat Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelik HK, Vardiman J, Lister TA, Bloomfield CD (2000) The Word Health Organization Classification of hematological malignancies report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997. Mod Pathol 13(2):193–207CrossRef Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelik HK, Vardiman J, Lister TA, Bloomfield CD (2000) The Word Health Organization Classification of hematological malignancies report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997. Mod Pathol 13(2):193–207CrossRef
4.
Zurück zum Zitat Vose JM, Bierman PJ, Anderson JR, Kessinger A, Pierson J, Nelson J, Prappier B, Schmit-Pokorny K, Weisenburger DD, Armitage JO (1992) Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 80(8):2142–2148CrossRef Vose JM, Bierman PJ, Anderson JR, Kessinger A, Pierson J, Nelson J, Prappier B, Schmit-Pokorny K, Weisenburger DD, Armitage JO (1992) Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 80(8):2142–2148CrossRef
5.
Zurück zum Zitat Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L, Melnick A, Coleman M, Leonard JP (2010) Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk 10(3):192–196CrossRef Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L, Melnick A, Coleman M, Leonard JP (2010) Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk 10(3):192–196CrossRef
6.
7.
Zurück zum Zitat Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliot G, Niemeyer CC (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkilating agents. Clin Cancer Res 14:309–317CrossRef Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliot G, Niemeyer CC (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkilating agents. Clin Cancer Res 14:309–317CrossRef
8.
Zurück zum Zitat Strumberg D, Harsdtrick A, Doll K, Hoffmann B, Seeber S (1996) Bendamustine hydrochloride activity against doxorubicin-resistent human breast carcinoma cell lines. Anticancer Drugs 7:415–421CrossRef Strumberg D, Harsdtrick A, Doll K, Hoffmann B, Seeber S (1996) Bendamustine hydrochloride activity against doxorubicin-resistent human breast carcinoma cell lines. Anticancer Drugs 7:415–421CrossRef
9.
Zurück zum Zitat Leoni LM, Bailey B, Reifert J (2003) SDX-105 (bendamustine), a clinically active antineoplastic agent posesses a unique mechanism of action. Blood; 102:640a Leoni LM, Bailey B, Reifert J (2003) SDX-105 (bendamustine), a clinically active antineoplastic agent posesses a unique mechanism of action. Blood; 102:640a
10.
Zurück zum Zitat Montillo M, Ricci F, Tedeschi A, Vismara E, Morra E (2010) Bendamustine: new perspective for an old drug in lymphoprolipherative disorders. Expert Rev Hematol 3(2):131–148CrossRef Montillo M, Ricci F, Tedeschi A, Vismara E, Morra E (2010) Bendamustine: new perspective for an old drug in lymphoprolipherative disorders. Expert Rev Hematol 3(2):131–148CrossRef
11.
Zurück zum Zitat Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD (2008) Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 26:204–210CrossRef Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD (2008) Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 26:204–210CrossRef
12.
Zurück zum Zitat Bremer K (2002) High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's lymphoma. J Cancer Res Clin Oncol 128:603–609CrossRef Bremer K (2002) High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's lymphoma. J Cancer Res Clin Oncol 128:603–609CrossRef
13.
Zurück zum Zitat Ujjani C, Cheson B (2011) Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial. Future Oncol 7(1):9–14CrossRef Ujjani C, Cheson B (2011) Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial. Future Oncol 7(1):9–14CrossRef
14.
Zurück zum Zitat Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244–1253CrossRef Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244–1253CrossRef
15.
Zurück zum Zitat SPSS Inc. (1998) SPSS for Windows, version 12.0. Chicago: SPSS. SPSS Inc. (1998) SPSS for Windows, version 12.0. Chicago: SPSS.
16.
Zurück zum Zitat Heider A, Niederle N (2001) Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphoma. Anticancer Drugs 12:725–729CrossRef Heider A, Niederle N (2001) Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphoma. Anticancer Drugs 12:725–729CrossRef
17.
Zurück zum Zitat Kath R, Blumenstengel K, Fricke HJ, Hoffken K (2001) Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Research Clin Oncol 127:48–54CrossRef Kath R, Blumenstengel K, Fricke HJ, Hoffken K (2001) Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Research Clin Oncol 127:48–54CrossRef
18.
Zurück zum Zitat Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP.(2011) The combination of bendamustine,bortezomib and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood, Jan 14 Epub Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP.(2011) The combination of bendamustine,bortezomib and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood, Jan 14 Epub
19.
Zurück zum Zitat Rummel MJ, Al-Batran SE, Kim SZ, Welsalu M, Hecker R, Kofahl-Krause D, Josten KM, Durk H, Rost A, Neise M, von Grunhagen U, Chow KU, Hansmann ML, Holzer D, Mitrou PS (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low grade non-Hodgkin’s lymphoma. J Clin Oncol 23(15):3383–3389CrossRef Rummel MJ, Al-Batran SE, Kim SZ, Welsalu M, Hecker R, Kofahl-Krause D, Josten KM, Durk H, Rost A, Neise M, von Grunhagen U, Chow KU, Hansmann ML, Holzer D, Mitrou PS (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low grade non-Hodgkin’s lymphoma. J Clin Oncol 23(15):3383–3389CrossRef
20.
Zurück zum Zitat Cheson BD, Friedberg JW, Kahl BS, Van der Jagt RH, Tremmel L (2010) Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 10(6):452–457CrossRef Cheson BD, Friedberg JW, Kahl BS, Van der Jagt RH, Tremmel L (2010) Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 10(6):452–457CrossRef
21.
Zurück zum Zitat Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, Ishizawa K, Yamamoto J, Watanabe T, Uike N, Choi I, Terui Y, Usuki K, Nagai H, Uoshima N, Tobinai K (2010) Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 101(9):2059–2064CrossRef Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, Ishizawa K, Yamamoto J, Watanabe T, Uike N, Choi I, Terui Y, Usuki K, Nagai H, Uoshima N, Tobinai K (2010) Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 101(9):2059–2064CrossRef
22.
Zurück zum Zitat Weide R, Pandorf A, Heymanns J et al (2004) Bendamustine/mitoxantrone/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20 positive indolent malignancies. Final results of a pilot study Leukemia and Lymphoma 45:2445–2449CrossRef Weide R, Pandorf A, Heymanns J et al (2004) Bendamustine/mitoxantrone/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20 positive indolent malignancies. Final results of a pilot study Leukemia and Lymphoma 45:2445–2449CrossRef
23.
Zurück zum Zitat Lissitchkov T, Arnaudov G, Peytchev D, Merkle KH (2006) Phase I/II study to evaluate dose limiting toxicity, massimum tolerated doses, and tolerability of bendamustine HCL in pre-treated patients with B-chronic lymphocytic leukemia (binet stage) requiring therapy. J Cancer Res Clin Oncol 132:99–104CrossRef Lissitchkov T, Arnaudov G, Peytchev D, Merkle KH (2006) Phase I/II study to evaluate dose limiting toxicity, massimum tolerated doses, and tolerability of bendamustine HCL in pre-treated patients with B-chronic lymphocytic leukemia (binet stage) requiring therapy. J Cancer Res Clin Oncol 132:99–104CrossRef
24.
Zurück zum Zitat Schoffski P, Seeland G, Engel H, Grunwald V, Paul H, Merkle K, Kowalski R, Ganser A (2000) Weekly administration of bendamustine a phase I study in patients with advanced progressive solid tumors. Ann Oncol 11:729–735CrossRef Schoffski P, Seeland G, Engel H, Grunwald V, Paul H, Merkle K, Kowalski R, Ganser A (2000) Weekly administration of bendamustine a phase I study in patients with advanced progressive solid tumors. Ann Oncol 11:729–735CrossRef
25.
Zurück zum Zitat Rasschaert M, Schrijvers D, Van den Brande J, Dyck J, Bosmans J, Merkle K, Vermorken JB (2007) A phase I study of bendamustine hydrochloride administered day 1 + 2 every 3 weeks in patients with solid tumors. Br J Cancer 96:1692–1698CrossRef Rasschaert M, Schrijvers D, Van den Brande J, Dyck J, Bosmans J, Merkle K, Vermorken JB (2007) A phase I study of bendamustine hydrochloride administered day 1 + 2 every 3 weeks in patients with solid tumors. Br J Cancer 96:1692–1698CrossRef
26.
Zurück zum Zitat Cheson BD, Wendtner CM, Pieper A, Dreyling M, Friedberg J, Hoelzer D, Moreau P, Gribben J, Knop S, Montillo M, Rummel M (2010) Optimal use of bendamustine in chronic lymphocytic leukemia, non Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 10:21–27CrossRef Cheson BD, Wendtner CM, Pieper A, Dreyling M, Friedberg J, Hoelzer D, Moreau P, Gribben J, Knop S, Montillo M, Rummel M (2010) Optimal use of bendamustine in chronic lymphocytic leukemia, non Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 10:21–27CrossRef
27.
Zurück zum Zitat Rummel MJ, Niederle N, Maschmeyer G, Banat A, von Gruenhagen U, Losem C, Heil G, Welslau M, Balser C, Kaiser U, Ballo H, Weidmann E, Duerk HA, Kofahl-Krause D, Roller F, Barth J, Hoelzer D, Hinke A and Brugger W. (2009) Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Abs. 405 :51st ASH Meeting Rummel MJ, Niederle N, Maschmeyer G, Banat A, von Gruenhagen U, Losem C, Heil G, Welslau M, Balser C, Kaiser U, Ballo H, Weidmann E, Duerk HA, Kofahl-Krause D, Roller F, Barth J, Hoelzer D, Hinke A and Brugger W. (2009) Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Abs. 405 :51st ASH Meeting
Metadaten
Titel
Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin’s lymphoma patients
A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL)
verfasst von
Luigi Rigacci
Benedetta Puccini
Sergio Cortelazzo
Gianluca Gaidano
Andrea Piccin
Alfonso D’Arco
Roberto Freilone
Sergio Storti
Enrico Orciuolo
Pier Luigi Zinzani
Francesco Zaja
Velia Bongarzoni
Monica Balzarotti
Delia Rota-Scalabrini
Caterina Patti
Marco Gobbi
Andrea Carpaneto
Anna Marina Liberati
Alberto Bosi
Emilio Iannitto
Publikationsdatum
01.07.2012
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 7/2012
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1422-5

Weitere Artikel der Ausgabe 7/2012

Annals of Hematology 7/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.